Key Takeaways
- Revenue up, margins down: Q2 FY27 revenue grew 19.5% YoY on stronger realizations, but EBITDA fell to ₹73.6 crores from ₹93.2 crores as raw material costs and supply-chain pressures compressed gross margins.
- Domestic B2B drove the top line, not the bottom line: The growth mix tilted toward lower-margin domestic B2B, so the revenue surge did not convert at the profit level.
- A dry monsoon reset farmer behavior: Prolonged dry spells made farmers delay sowing and withhold crop-protection spend until crops showed survival, compressing demand in August and September.
- Brazil is a 2–3 year story, not a near-term catalyst: The subsidiary has registrations underway and a small B2B office, but management sees a multi-year timeline before the geography contributes materially.
- What to watch next quarter: Whether Q3 stays subdued as flagged, whether the patented Rabi insecticide gains traction, and whether Q4 margin recovery actually materializes.
Top-Line Growth & Its Composition
- Realization-led, not volume-led: The 19.5% YoY revenue increase was driven primarily by higher realizations across key products, partly reflecting pass-through of higher raw material prices; volume increases occurred only in some products.
- Domestic B2B was the engine: Growth was predominantly in domestic markets, with the B2B segment contributing the bulk; B2C also grew but was not the primary driver.
- Export share and ambition: Exports currently contribute almost 20% of total business; management targets a proportionate increase to 25% over three years, with domestic business also growing in absolute terms.
- Export growth geographies: Latin America and Southeast Asia are the key markets driving export growth.
Shail Shah: "So currently exports is almost 20% of our total business. And we see that going forward in the 3 years' time, this could go up to 25% with -- as the growth is also being planned for the domestic business, proportionately we see that there will be growth in domestic also."
Margin Pressure: Causes & Recovery Path
- Raw material costs did half the damage: Approximately 50% of the margin pressure came from higher raw material procurement costs, 20–30% from supply-chain related issues or costs, and the remaining 20% from other factors including high-margin products.
- Operating costs added incremental weight: Increases in power and fuel expenses, plus routine annual manpower cost escalation, compounded the gross-margin squeeze at the EBITDA and PAT levels.
- Sequential improvement already underway: Some cost optimization measures helped improve EBITDA sequentially in Q2 FY27, even as the YoY decline remained steep.
- Recovery timeline is back-end loaded: Management expects another quarter of certain pressures in Q3, with margins normalizing in Q4 as realizations improve with the upcoming season and pre-placement period.
- Backward integration as structural margin lever: R&D is developing opportunities to backward-integrate key active ingredients and technicals, aiming to reduce import reliance, secure supply, and improve margins over time.
Shail Shah: "So we see that another quarter or so, we see that it could be, where there could be certain pressures further. But I think in the Q4, we could see that the margins again coming up back to the normal levels."
Monsoon, Farmer Behavior & Near-Term Demand
- Below-normal monsoon disrupted the playbook: Uneven rainfall and prolonged dry spells in Maharashtra and Karnataka raised concerns over final crop productivity; lower reservoir levels in southern India could affect irrigation availability for the Rabi season.
- Farmers turned cautious: Farmers delayed sowing to gain visibility on rainfall, shifted 5–10% of acreage to less water-intensive or shorter-duration crops, and withheld crop-protection spend when early-stage rain deficits threatened crop survival.
- Demand softened through the quarter: The year began reasonably well, but as El Niño sentiment built, demand started dropping; by August and September, the focus shifted entirely to inventory liquidation at the farmer level, subduing domestic demand across both B2B and B2C.
- Rabi is a smaller, but targeted, opportunity: The company is Kharif-dominated and Rabi is not a large share of business; even so, management expects to do better than last year in Rabi, supported by a newly launched patented insecticide and an expanded distribution network.
Shail Shah: "So there, once a crop is 45 days-50 days old and the farmer is a bit confident that now the crop will survive, there the farmer is inclined to spend towards crop protection because that is how we can save or increase his yield. But if there are any chances where they see that in the early stages where because of a huge gap or a deficit in the early days where the rain is not sufficient, then the farmers are a bit reluctant to use that because they don't see that visibility of the crop surviving the entire cycle."
International Expansion: Brazil & Latin America
- Brazil presence is early-stage: A subsidiary was established three years ago; the company has gathered registrations and set up a small administration office for B2B business, but scaling is still ahead.
- Logistics are a current drag: Vessel availability constraints and extended transit times for consignments to Brazil are creating challenges for Indian suppliers, alongside increased cost pressures.
- Sizable business is 2–3 years out: Management estimates a 2–3 year timeline to build a decent portfolio of registrations with sufficient variability to do meaningful business in Brazil.
- Platform scaling adds another layer: Setting up a platform to scale within Brazil and use it as a base for other Latin American countries will take at least another year or two.
- Latin America as a future export pillar: Over 2–3 years, Latin America is expected to contribute a good portion of export business.
Shail Shah: "2 years-3 years timeline, we see that we will be doing sizable business in this geography once you have acquired decent number of registrations with a good enough variability in the portfolio that we have to offer to that market."
Product Strategy & Differentiation
- Patented combinations are the moat: The company creates unique formulation combinations from existing and newer chemistries, patents them, and positions them as multi-problem solutions for farmers, creating differentiation from generic products.
- New Rabi launch as an anchor: A patented insecticide launched last month is positioned to serve as an anchor product for the Rabi season, helping move other products through the distribution network.
- International patent pipeline building: Registrations for patented products in international markets have been underway for three years; management expects registrations with IPR protection to come through in 2–3 years, helping maintain margins.
- R&D investment set to rise: Planned increases in R&D spending, likely from next year onward, will support product development, differentiated formulations, and backward integration of key technicals.
Shail Shah: "So we try to create a unique combination of formulation from the existing and the newer chemistries that are available. And we try to patent them. ... these patented combinations help the farmers to solve multiple problems by using one product. And it helps us to create a niche in that market where we are able to differentiate from other existing products or generics that are there."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Margin normalization | Margins to return to normal levels, driven by improved realizations and pre-placement period | Q4 FY27 |
| Sequential EBITDA improvement | EBITDA margins to improve sequentially in coming quarters, supported by Rabi products and Q4 pre-placement | Q3 and Q4 FY27 |
| Q4 better than Q3 | Both PAT and EBITDA margins confirmed to be better in Q4 than Q3 | Q4 FY27 |
| Rabi performance | Do at least better than last year in Rabi season despite macro challenges | Rabi season |
| Export contribution | Export share of total revenue to increase from ~20% to 25% | 3 years |
| Brazil sizable business | Achieve meaningful revenue in Brazil once sufficient registrations and portfolio variability are in place | 2–3 years |
| Brazil platform scaling | Set up a platform to scale in Brazil and expand to other Latin American countries | At least 1–2 years |
| Latin America export contribution | Latin America to contribute a good portion of export business | 2–3 years |
| International patent registrations | Registrations with IPR protection to come through in international markets | 2–3 years |
| R&D investment increase | R&D spend to increase to support product development and backward integration | Likely from next year onward |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue from operations | ₹558 cr, +19.5% YoY |
| H1 FY27 revenue from operations | ₹944 cr, +12% YoY |
| EBITDA | ₹73.6 cr, -21% YoY from ₹93.2 cr |
| EBITDA margin | 13.2%, vs 13.2% in Q2 FY26 (Q2 FY26 EBITDA margin not stated on these pages) |
| H1 FY27 EBITDA margin | 12.3% |
| Profit after tax | ₹44.6 cr, vs ₹58.5 cr in Q2 FY26 |
| H1 FY27 profit after tax | ₹71 cr |
| Gross profit margin | 34%, declined from 40% (40% figure stated by analyst, not confirmed by management on these pages) |
| Export revenue contribution | ~20% of total business |
| R&D investment | ~2.5% of revenue |
| Raw material imported | 40% to 45% of total requirement, from China |
| Normalized other income | ~₹2 cr per quarter, excluding asset sales |
| Cumulative rainfall (IMD) | ~87% of long period average, lowest since 2015 |